Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection, Clinical Pharmacokinetics, vol.29, issue.1, pp.46-65, 1995. ,
DOI : 10.2165/00003088-199529010-00006
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships ,
Concentration-controlled zidovudine therapy*, Clinical Pharmacology & Therapeutics, vol.337, issue.3, pp.331-339, 1998. ,
DOI : 10.1016/S0009-9236(98)90182-5
Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir, Antimicrobial Agents and Chemotherapy, vol.45, issue.1, pp.236-278, 2001. ,
DOI : 10.1128/AAC.45.1.236-242.2001
High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy, Clinical Pharmacokinetics, vol.30, issue.12, pp.1267-78, 2005. ,
DOI : 10.2165/00003088-200544120-00005
Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy, Fundamental and Clinical Pharmacology, vol.40, issue.3, pp.373-83, 2005. ,
DOI : 10.1097/00002030-200305230-00007
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART, British Journal of Clinical Pharmacology, vol.46, issue.4, pp.390-403, 2005. ,
DOI : 10.1002/sim.1619
Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach, Social Science & Medicine, vol.54, issue.10, pp.1481-96, 2002. ,
DOI : 10.1016/S0277-9536(01)00125-3
Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.744, issue.2, pp.227-267, 2000. ,
DOI : 10.1016/S0378-4347(00)00225-5
Ways to fit a PK model with some data below the quantification limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001. ,
DOI : 10.1023/A:1012299115260
Nonlinear Mixed Effects Models for Repeated Measures Data, Biometrics, vol.46, issue.3, pp.673-87, 1990. ,
DOI : 10.2307/2532087
Mixed-effect models in S and Splus, 2000. ,
R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2005. ,
Statistical predictor identification, Annals of the Institute of Statistical Mathematics, vol.3, issue.1, pp.203-217, 1973. ,
DOI : 10.1007/BF02506337
Population pharmacokinetics of zidovudine, Clinical Pharmacology and Therapeutics, vol.48, issue.2, pp.161-168, 1990. ,
DOI : 10.1038/clpt.1990.131
Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity, European Journal of Clinical Pharmacology, vol.I, issue.2, pp.397-407, 1993. ,
DOI : 10.1007/BF00315509
Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex, Antimicrobial Agents and Chemotherapy, vol.39, issue.10, pp.2309-2324, 1995. ,
DOI : 10.1128/AAC.39.10.2309
Population Pharmacokinetics of Didanosine in Patients with Human Immunodeficiency Virus Infection, Journal of Infectious Diseases, vol.173, issue.1, p.273, 1996. ,
DOI : 10.1093/infdis/173.1.273
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials, Antimicrob Agents Chemother, vol.43, issue.12, pp.3025-3034, 1999. ,
Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects, Antimicrobial Agents and Chemotherapy, vol.44, issue.8, pp.2052-60, 2000. ,
DOI : 10.1128/AAC.44.8.2052-2060.2000
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators, Antimicrob Agents Chemother, vol.43, issue.1, pp.121-129, 1999. ,
Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy, Antimicrobial Agents and Chemotherapy, vol.49, issue.8, pp.3361-3367, 2005. ,
DOI : 10.1128/AAC.49.8.3361-3366.2005
Pharmacokinetics of 3TC (GR109714X) Administered With and Without Food to HIV-infected Patients, Drug Investigation, vol.4, issue.2, pp.70-74, 1993. ,
DOI : 10.1007/BF03258455
Lamivudine/Zidovudine as a Combined Formulation Tablet: Bioequivalence Compared with Lamivudine and Zidovudine Administered Concurrently and the Effect of Food on Absorption, The Journal of Clinical Pharmacology, vol.277, issue.Suppl. 2, pp.593-605, 1999. ,
DOI : 10.1177/00912709922008209
Therapeutic Drug Monitoring, Drugs, vol.40, issue.8, pp.741-53, 2003. ,
DOI : 10.2165/00003495-200363080-00002
Relationship between Dideoxyinosine Exposure, CD4 Counts, and p24 Antigen Levels in Human Immunodeficiency Virus Infection, Annals of Internal Medicine, vol.116, issue.7, pp.562-568, 1992. ,
DOI : 10.7326/0003-4819-116-7-562
Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy, Fundamental and Clinical Pharmacology, vol.63, issue.5 ,
DOI : 10.1016/S0378-4347(00)83399-X